A phase I, dose-escalation study to evaluate the safety and efficacy of Gimeracil/oteracil/tegafur (S-1) given concurrently with chemoradiotherapy for patients with head and neck cancer
Latest Information Update: 05 Dec 2015
Price :
$35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Parotid cancer
- Focus Adverse reactions
- 05 Dec 2015 New trial record